Mirikizumab for Ulcerative Colitis, with Marla Dubinsky, MD; Marla Dubinsky, MD, discusses findings from the LUCENT program and their role in the recent FDA approval of mirikizumab for ulcerative colitis.

Press/Media

Period31 Oct 2023

Media coverage

2

Media coverage

  • TitleMirikizumab for Ulcerative Colitis, with Marla Dubinsky, MD; Marla Dubinsky, MD, discusses findings from the LUCENT program and their role in the recent FDA approval of mirikizumab for ulcerative colitis.
    Media name/outletConsultant Live
    Country/TerritoryUnited States
    Date31/10/23
    PersonsMarla Dubinsky
  • TitleMirikizumab for Ulcerative Colitis, with Marla Dubinsky, MD
    Media name/outletHCP Live
    Country/TerritoryUnited States
    Date31/10/23
    PersonsMarla Dubinsky